Trial reportJournal of clinical hypertension (Greenwich, Conn.)2006
Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 54 citations in OpenAlex.
- A randomized controlled trial on home blood pressure monitoring and quality of care in stage 2 and 3 hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Trial
- Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.Drugs in R&D · 2013Trial
- Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors.Journal of clinical hypertension (Greenwich, Conn.) · 2010Trial
- Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension.Journal of human hypertension · 2010Trial
- A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.Journal of human hypertension · 2008Trial
- Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy.Journal of clinical hypertension (Greenwich, Conn.) · 2007Trial
- The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.Journal of clinical hypertension (Greenwich, Conn.) · 2007Trial
- Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial.Journal of women's health (2002)Trial
- Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.Vascular health and risk management · 2013Review
- Single-pill telmisartan and amlodipine: a rational combination for the treatment of hypertension.Drugs · 2011Review
- Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.The European journal of health economics : HEPAC : health economics in prevention and care · 2011Article
- Introducing candesartan 32 mg plus hydrochlorothiazide 25 mg in previously untreated patients with severe essential hypertension.Pragmatic and observational research · 2011Article
- Combination therapy in hypertension: An update.Diabetology & metabolic syndrome · 2010Article
- The clock is ticking: the case for achieving more rapid control of hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2010Article
- Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy.Journal of clinical hypertension (Greenwich, Conn.) · 2009Review
- The risks and benefits of initial irbesartan/hydrochlorothiazide combination therapy in patients with severe hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2009Review
- Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension.Vascular health and risk management · 2009Review
- Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice.Vascular health and risk management · 2009Article
- Initial combination therapy for rapid and effective control of moderate and severe hypertension.Journal of human hypertension · 2009Review
- Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.Journal of human hypertension · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe hypertension is difficult to control. This prospective, randomized, double-blind, active-controlled, multicenter trial compared efficacy and safety of once-daily irbesartan/hydrochlorothiazide (HCTZ) combination therapy with irbesartan monotherapy in severe hypertension. Patients who were untreated or uncontrolled on monotherapy (seated diastolic blood pressure [BP] > or =110 mm Hg) received fixed-dose irbesartan 150 mg/HCTZ 12.5 mg combination therapy for 7 weeks, force-titrated to irbesartan 300 mg/HCTZ 25 mg at week 1 (n=468); or irbesartan 150 mg monotherapy, force-titrated to 300 mg at week 1 (n=269). Significantly more patients on combination therapy achieved seated diastolic BP <90 mm Hg at week 5 (primary end point) compared with monotherapy recipients (47.2% vs 33.2%; P=.0005). Likewise, significantly more patients attained goals per the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) (<140/90 mm Hg) at week 5 (34.6% vs 19.2%, respectively; P<.0001), while the mean difference between combination and monotherapy in seated diastolic BP and seated systolic BP was 4.7 mm Hg and 9.7 mm Hg (P<.0001). Greater and more rapid BP reduction with irbesartan/HCTZ was achieved without additional side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.